We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Scalp Cooling System Reduces Cancer Patients Hair Loss

By HospiMedica International staff writers
Posted on 02 Jul 2019
Print article
Image: The fourth-generation DigniCap Delta scalp cooling system (Photo courtesy of Dignitana).
Image: The fourth-generation DigniCap Delta scalp cooling system (Photo courtesy of Dignitana).
A fourth-generation medical cooling device offers cancer patients the ability to minimize alopecia (hair loss) during chemotherapy treatments.

The Dignitana (Lund, Sweden) DigniCap Delta scalp cooling system is indicated for the prevention of chemotherapy-induced hair loss in patients with solid tumors. The system works by circulating liquid coolant through a flexible cooling wrap and an adjustable thermal cap that optimize scalp cooling outcomes. The cooling wrap is placed directly on the head to deliver consistent, controlled cooling to the scalp, while the outer thermal neoprene cap insulates and secures it tightly in place, with two built-in sensors continuously monitoring scalp temperature in order to maintain optimal cooling throughout.

Key system features include a quick-disconnect to accommodate bathroom breaks, an intuitive touch screen interface to simplify system operation, and flash memory that makes it possible to save data from each scalp cooling treatment and facilitates software upgrades. A built-in safety sensor ensures cooling temperature does not drop below freezing point. The cooling cap itself is available in multiple sizes to insure a personalized fit, and has a smooth inner surface to enable optimal contact between scalp and cap. Two independently controlled systems can be used for simultaneous treatment of two patients.

“DigniCap Delta changes everything about the way scalp cooling is done today. We are thrilled to offer patients and clinicians this state-of-the-art advancement in cancer care,” said William Cronin, CEO of Dignitana. “The clearance of Delta now provides a clear pathway for growth in the important US market and beyond. It is the biggest step yet in the evolution of Dignitana, and is the result of a tremendous effort from our staff, partner sites, regulatory team and contract manufacturer.”

As the temperature of the scalp is lowered, the subsequent blood vessel vasoconstriction reduces the amount of chemotherapy agents that reach it, as well as reducing uptake of drugs in the hair follicles due to decreased intra-follicular metabolic rate. The combined actions are thought to reduce the effect chemotherapy has on the cells, which may reduce hair loss.

Related Links:
Dignitana

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Multilevel Self-Loading Stretcher
CARRERA XL

Print article

Channels

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more